Advanced search
Publication Cover
International Medical Case Reports Journal Volume 17, 2024 - Issue
Submit an article Journal homepage
163
Views
0
CrossRef citations to date
0
Altmetric
Case reports

Case Series: Sacubitril/Valsartan Role for Chemotherapy-Induced Cardiotoxicity: An in-Depth Investigation in Saudi Arabia

Abdullah Alshammari1 Clinical Pharmacy Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi ArabiaView further author information
,
Basmah Ahmed Qasem1 Clinical Pharmacy Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi ArabiaView further author information
,
Nouf Ahmed Almatrafi1 Clinical Pharmacy Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi ArabiaView further author information
,
Lujain Mofareh Alharbi1 Clinical Pharmacy Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi ArabiaView further author information
,
Abeer Abdulhadi Alhuthali2 Clinical Pharmacy Department, King Abdullah Medical City, Makkah, Saudi ArabiaView further author information
,
Attiah Abdulrahman Khobrani2 Clinical Pharmacy Department, King Abdullah Medical City, Makkah, Saudi ArabiaView further author information
&
Mohammed Alnuhait1 Clinical Pharmacy Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi ArabiaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-5279-5437View further author information
ORCID Icon show all
Pages 35-41 | Received 12 Nov 2023, Accepted 16 Jan 2024, Published online: 18 Jan 2024

References

  • Okwuosa TM, Anzevino S, Rao R. Cardiovascular disease in cancer survivors. Postgrad Med J. 2017;93(1096):82–90. doi:10.1136/postgradmedj-2016-134417
  • Canale ML, Coviello K, Solarino G, et al. Case Series: recovery of Chemotherapy-Related Acute Heart Failure by the Combined Use of Sacubitril Valsartan and Wearable Cardioverter Defibrillator: a Novel Winning Combination in Cardio-Oncology. Front Cardiovasc Med. 2022;9:801143. doi:10.3389/fcvm.2022.801143
  • Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981–1988. doi:10.1161/circulationaha.114.013777
  • Iqubal A, Iqubal MK, Sharma S, et al. Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: old drug with a new vision. Life Sci. 2019;218:112–131. doi:10.1016/j.lfs.2018.12.018
  • Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768–2801. doi:10.1093/eurheartj/ehw211
  • Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst. 2010;102(1):14–25. doi:10.1093/jnci/djp440
  • Ahles TA, Saykin AJ. Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer. 2007;7(3):192–201. doi:10.1038/nrc2073
  • Heidenreich PA, Bozkurt B, Aguilar D. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Card Fail. 2022;28(5):e1–e167. doi:10.1016/j.cardfail.2022.02.010
  • McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004. doi:10.1056/NEJMoa1409077
  • De Vecchis R, Paccone A. A case series about the favorable effects of sacubitril/valsartan on anthracycline cardiomyopathy. SAGE Open Med Case Rep. 2020;8:2050313x20952189. doi:10.1177/2050313x20952189
  • Sheppard CE, Anwar M. The use of sacubitril/valsartan in anthracycline-induced cardiomyopathy: a mini case series. J Oncol Pharm Pract. 2019;25(5):1231–1234. doi:10.1177/1078155218783238
  • Gregorietti V, Fernandez TL, Costa D, Chahla EO, Daniele AJ. Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy. Cardiooncology. 2020;6(1):24. doi:10.1186/s40959-020-00078-4
  • Pascual-Figal D, Bayés-Genis A, Beltrán-Troncoso P, et al. Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review. Front Cardiovasc Med. 2021;8:754499. doi:10.3389/fcvm.2021.754499
  • Sobiborowicz-Sadowska AM, Kamińska K, Cudnoch-Jędrzejewska A. Neprilysin Inhibition in the Prevention of Anthracycline-Induced Cardiotoxicity. Cancers. 2023;15(1):312. doi:10.3390/cancers15010312

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.